{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T18:37:53Z","timestamp":1792607873382,"version":"4.5.0"},"reference-count":128,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T00:00:00Z","timestamp":1754611200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007446","name":"King Khalid University","doi-asserted-by":"publisher","award":["RGP2 \/82\/46"],"award-info":[{"award-number":["RGP2 \/82\/46"]}],"id":[{"id":"10.13039\/501100007446","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.cyto.2025.157010","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T12:00:54Z","timestamp":1755086454000},"page":"157010","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Dysregulation of the leukotriene pathway in Parkinson's disease: The potential role of montelukast"],"prefix":"10.1016","volume":"194","author":[{"given":"Sultan M.","family":"Alshahrani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayder M.","family":"Al-kuraishy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali I.","family":"Al-Gareeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa M.","family":"Shokr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Alexiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marios","family":"Papadakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaber El-Saber","family":"Batiha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.cyto.2025.157010_bb0005","first-page":"1","article-title":"The interplay of aging, genetics, and environmental factors in the pathogenesis of Parkinson\u2019s disease","volume":"81","author":"Pang","year":"2019","journal-title":"Transl. Neurodegener."},{"key":"10.1016\/j.cyto.2025.157010_bb0010","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.00356","article-title":"Modeling Parkinson's disease with the alpha-synuclein protein","volume":"11","author":"G\u00f3mez-Benito","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.cyto.2025.157010_bb0015","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00210-023-02656-6","article-title":"Does vitamin D protect or treat Parkinson's disease? A narrative review","volume":"397","author":"Al-kuraishy","year":"2024","journal-title":"Naunyn Schmiedeberg's Arch. Pharmacol."},{"key":"10.1016\/j.cyto.2025.157010_bb0020","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1111\/jcmm.17784","article-title":"NF-\u03baB\/NLRP3 inflammasome axis and risk of Parkinson\u2019s disease in type 2 diabetes mellitus: a narrative review and new perspective","volume":"27","author":"Alrouji","year":"2023","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.cyto.2025.157010_bb0025","doi-asserted-by":"crossref","first-page":"6107","DOI":"10.1007\/s11033-023-08459-5","article-title":"Orexin pathway in Parkinson\u2019s disease: a review","volume":"50","author":"Alrouji","year":"2023","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.cyto.2025.157010_bb0030","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s10787-022-01125-5","article-title":"SIRT1 pathway in Parkinson\u2019s disease: a faraway snapshot but so close","volume":"31","author":"Batiha","year":"2023","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.cyto.2025.157010_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2023.102143","article-title":"Calprotectin in parkinsonian disease: anticipation and dedication","volume":"93","author":"Al-kuraishy","year":"2024","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.cyto.2025.157010_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2023.102075","article-title":"The conceivable role of prolactin hormone in Parkinson disease: the same goal but with different ways","volume":"91","author":"Al-kuraishy","year":"2023","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.cyto.2025.157010_bb0045","doi-asserted-by":"crossref","first-page":"e01063","DOI":"10.1002\/prp2.1063","article-title":"Pros and cons for statins use and risk of Parkinson's disease: an updated perspective","volume":"11","author":"Al-kuraishy","year":"2023","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.cyto.2025.157010_bb0050","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s43440-023-00500-5","article-title":"DPP-4 inhibitors and type 2 diabetes mellitus in Parkinson\u2019s disease: a mutual relationship","volume":"75","author":"Alrouji","year":"2023","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.cyto.2025.157010_bb0055","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13024-023-00622-7","article-title":"Neuropathology of incidental Lewy body & prodromal Parkinson\u2019s disease","volume":"18","author":"Koeglsperger","year":"2023","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.cyto.2025.157010_bb0060","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1007\/s00210-023-02726-9","article-title":"Irisin\/PGC-1\u03b1\/FNDC5 pathway in Parkinson's disease: truth under the throes","volume":"397","author":"Ali","year":"2024","journal-title":"Naunyn Schmiedeberg's Arch. Pharmacol."},{"key":"10.1016\/j.cyto.2025.157010_bb0065","doi-asserted-by":"crossref","first-page":"70","DOI":"10.4103\/bc.bc_42_19","article-title":"Involvement of orexinergic system in psychiatric and neurodegenerative disorders: a scoping review","volume":"6","author":"Al-Kuraishy","year":"2020","journal-title":"Brain Circ."},{"key":"10.1016\/j.cyto.2025.157010_bb0070","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.616820","article-title":"Neurotransmitters, cell types, and circuit mechanisms of motor skill learning and clinical applications","volume":"12","author":"Tian","year":"2021","journal-title":"Front. Neurol."},{"key":"10.1016\/j.cyto.2025.157010_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2025.177419","article-title":"Dysregulation of serotonergic neurotransmission in Parkinson disease: a key duet","volume":"995","author":"Khowdiary","year":"2025","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.cyto.2025.157010_bb0080","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s10286-021-00801-w","article-title":"Dyskinesia-hyperpyrexia syndrome in Parkinson\u2019s disease: a systematic review","volume":"31","author":"Wang","year":"2021","journal-title":"Clin. Auton. Res."},{"key":"10.1016\/j.cyto.2025.157010_bb0085","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41583-021-00542-9","article-title":"Motor and non-motor circuit disturbances in early Parkinson disease: which happens first?","volume":"23","author":"Blesa","year":"2022","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.cyto.2025.157010_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2022.101834","article-title":"Premotor, nonmotor and motor symptoms of Parkinson\u2019s disease: a new clinical state of the art","volume":"84","author":"Leite Silva","year":"2023","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.cyto.2025.157010_bb0095","doi-asserted-by":"crossref","first-page":"10382","DOI":"10.1523\/JNEUROSCI.1753-21.2021","article-title":"Input zone-selective dysrhythmia in motor thalamus after dopamine depletion","volume":"41","author":"Nakamura","year":"2021","journal-title":"J. Neurosci."},{"key":"10.1016\/j.cyto.2025.157010_bb0100","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.2174\/1570159X21666230731110709","article-title":"Future directions for developing non-dopaminergic strategies for the treatment of Parkinson's disease","volume":"22","author":"van Wamelen","year":"2023","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.cyto.2025.157010_bb0105","doi-asserted-by":"crossref","first-page":"3587","DOI":"10.1093\/brain\/awad150","article-title":"Advances in understanding the function of alpha-synuclein: implications for Parkinson\u2019s disease","volume":"146","author":"Calabresi","year":"2023","journal-title":"Brain"},{"key":"10.1016\/j.cyto.2025.157010_bb0110","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41419-023-05672-9","article-title":"Alpha-synuclein in Parkinson\u2019s disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction","volume":"14","author":"Calabresi","year":"2023","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.cyto.2025.157010_bb0115","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22158338","article-title":"The prion-like spreading of alpha-synuclein in Parkinson's disease: update on models and hypotheses","volume":"22","author":"Jan","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cyto.2025.157010_bb0120","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.3390\/biom11101508","article-title":"Mitochondrial dysfunction, protein misfolding and neuroinflammation in parkinson\u2019s disease: roads to biomarker discovery","volume":"11","author":"Picca","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.cyto.2025.157010_bb0125","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12134427","article-title":"Levodopa-induced dyskinesias in Parkinson's disease: an overview on pathophysiology, clinical manifestations, therapy management strategies and future directions","volume":"12","author":"di Biase","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.cyto.2025.157010_bb0130","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1001\/jamaneurol.2022.0003","article-title":"Assessment of risk factors and early presentations of Parkinson disease in primary Care in a Diverse UK population","volume":"79","author":"Simonet","year":"2022","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.cyto.2025.157010_bb0135","article-title":"Cognitive impairment in Parkinson's disease: epidemiology, clinical profile, protective and risk factors","volume":"11","author":"Gonzalez-Latapi","year":"2021","journal-title":"Behav. Sci. (Basel)"},{"key":"10.1016\/j.cyto.2025.157010_bb0140","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1002\/mdc3.13523","article-title":"Age cutoff for early-onset Parkinson\u2019s disease: recommendations from the International Parkinson and Movement Disorder Society task force on early onset Parkinson\u2019s disease","volume":"9","author":"Mehanna","year":"2022","journal-title":"Mov. Disord. Clin. Pract."},{"key":"10.1016\/j.cyto.2025.157010_bb0145","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41531-023-00549-2","article-title":"Does black vs. white race affect practitioners' appraisal of Parkinson's disease?","volume":"9","author":"Harris","year":"2023","journal-title":"NPJ Parkinsons Dis."},{"key":"10.1016\/j.cyto.2025.157010_bb0150","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.3390\/genes14112097","article-title":"The landscape of monogenic Parkinson\u2019s disease in populations of non-European ancestry: a narrative review","volume":"14","author":"Koros","year":"2023","journal-title":"Genes (Basel)"},{"issue":"12","key":"10.1016\/j.cyto.2025.157010_bb0155","article-title":"Peripheral inflammatory immune response differs among sporadic and familial Parkinson's disease","volume":"9","author":"Mu\u00f1oz-Delgado","year":"2023","journal-title":"NPJ Park. Dis."},{"key":"10.1016\/j.cyto.2025.157010_bb0160","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s10038-022-01058-5","article-title":"Molecular genetics of Parkinson\u2019s disease: contributions and global trends","volume":"68","author":"Funayama","year":"2023","journal-title":"J. Hum. Genet."},{"key":"10.1016\/j.cyto.2025.157010_bb0165","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0140-6736(23)01419-8","article-title":"The epidemiology of Parkinson\u2019s disease","volume":"403","author":"Ben-Shlomo","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.cyto.2025.157010_bb0170","doi-asserted-by":"crossref","DOI":"10.3390\/genes13030471","article-title":"Monogenic Parkinson\u2019s disease: genotype, phenotype, pathophysiology, and genetic testing","volume":"13","author":"Jia","year":"2022","journal-title":"Genes"},{"key":"10.1016\/j.cyto.2025.157010_bb0175","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1007\/s10787-024-01557-1","article-title":"Leukotriene signaling in neurodegeneration: implications for treatment strategies","volume":"32","author":"Sharma","year":"2024","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.cyto.2025.157010_bb0180","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.neulet.2018.05.052","article-title":"Effect of montelukast in experimental model of Parkinson\u2019s disease","volume":"682","author":"Nagarajan","year":"2018","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.cyto.2025.157010_bb0185","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2174\/1871527320666210902163756","article-title":"Targeted delivery of Montelukast for the treatment of Alzheimer's disease","volume":"21","author":"Datusalia","year":"2021","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"10.1016\/j.cyto.2025.157010_bb0190","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s13195-021-00892-7","article-title":"Leukotriene receptor antagonist use and cognitive decline in normal cognition, mild cognitive impairment, and Alzheimer\u2019s dementia","volume":"13","author":"Xiong","year":"2021","journal-title":"Alzheimer\u2019s Res Ther"},{"key":"10.1016\/j.cyto.2025.157010_bb0195","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22115606","article-title":"Potential effects of leukotriene receptor antagonist montelukast in treatment of neuroinflammation in Parkinson's disease","volume":"22","author":"Wallin","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cyto.2025.157010_bb0200","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.brainres.2014.05.026","article-title":"Regulation of rotenone-induced microglial activation by 5-lipoxygenase and cysteinyl leukotriene receptor 1","volume":"1572","author":"Zhang","year":"2014","journal-title":"Brain Res."},{"key":"10.1016\/j.cyto.2025.157010_bb0205","doi-asserted-by":"crossref","DOI":"10.3390\/cells11132123","article-title":"Arachidonic acid cascade and eicosanoid production are elevated while LTC4 synthase modulates the lipidomics profile in the brain of the HIVgp120-transgenic mouse model of NeuroHIV","volume":"11","author":"Yuan","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.cyto.2025.157010_bb0210","doi-asserted-by":"crossref","unstructured":"G.W. Bisset, T. V. Bliss, Wilhelm Siegmund Feldberg, C.B.E., 19 November 1900\u201323 October 1993., 1997. doi:https:\/\/doi.org\/10.1098\/rsbm.1997.0009.","DOI":"10.1098\/rsbm.1997.0009"},{"key":"10.1016\/j.cyto.2025.157010_bb0215","doi-asserted-by":"crossref","first-page":"295","DOI":"10.37506\/ijfmt.v15i2.14325","article-title":"Leukotrienes and inflammation \u2013 a review","volume":"15","author":"Butola","year":"2021","journal-title":"Indian J. Forensic Med. Toxicol."},{"key":"10.1016\/j.cyto.2025.157010_bb0220","first-page":"1","article-title":"Paracetamol: the potential therapeutic pathways defining its clinical use","author":"Al-Kuraishy","year":"2025","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.cyto.2025.157010_bb0225","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2147\/JEP.S277720","article-title":"Montelukast: the new therapeutic option for the treatment of epilepsy","volume":"13","author":"Tesfaye","year":"2021","journal-title":"J. Exp. Pharmacol."},{"key":"10.1016\/j.cyto.2025.157010_bb0230","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.3390\/nu6104043","article-title":"Effects of perioperative supplementation with omega-3 fatty acids on leukotriene B4 and leukotriene B5 production by stimulated neutrophils in patients with colorectal cancer: a randomized, placebo-controlled intervention trial","volume":"6","author":"Sorensen","year":"2014","journal-title":"Nutrients"},{"key":"10.1016\/j.cyto.2025.157010_bb0235","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1146\/annurev-pathmechdis-111523-023509","article-title":"Cysteinyl leukotrienes in allergic inflammation","volume":"20","author":"Lee","year":"2025","journal-title":"Annu. Rev. Pathol. Mech. Dis."},{"key":"10.1016\/j.cyto.2025.157010_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamcr.2021.119203","article-title":"Leukotriene C4 synthase is a novel PPAR\u03b3 target gene, and leukotriene C4 and D4 activate adipogenesis through cysteinyl LT1 receptors in adipocytes","volume":"1869","author":"Fujimori","year":"2022","journal-title":"Biochim. Biophys. Acta, Mol. Cell Res."},{"key":"10.1016\/j.cyto.2025.157010_bb0245","doi-asserted-by":"crossref","DOI":"10.1080\/21505594.2025.2502555","article-title":"Unraveling cysteinyl leukotrienes and their receptors in inflammation through the brain-gut-lung axis","volume":"16","author":"Liu","year":"2025","journal-title":"Virulence"},{"key":"10.1016\/j.cyto.2025.157010_bb0250","doi-asserted-by":"crossref","DOI":"10.3390\/ph15091039","article-title":"Leukotrienes vs. montelukast\u2014activity, metabolism, and toxicity hints for repurposing","volume":"15","author":"Marques","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.cyto.2025.157010_bb0255","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1042\/CS20190657","article-title":"Eicosanoid receptors as therapeutic targets for asthma","volume":"135","author":"Powell","year":"2021","journal-title":"Clin. Sci."},{"key":"10.1016\/j.cyto.2025.157010_bb0260","doi-asserted-by":"crossref","DOI":"10.3390\/cells10051098","article-title":"Control of macrophage inflammation by P2Y purinergic receptors","volume":"10","author":"Klaver","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.cyto.2025.157010_bb0265","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s00508-021-01981-1","article-title":"FDA warning montelukast 03.2020\u2014statement of the Austrian working group of pediatric pulmonology and allergology","volume":"134","author":"Zschocke","year":"2022","journal-title":"Wien. Klin. Wochenschr."},{"key":"10.1016\/j.cyto.2025.157010_bb0270","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.ymthe.2021.10.014","article-title":"The neutralization effect of montelukast on SARS-CoV-2 is shown by multiscale in silico simulations and combined in vitro studies","volume":"30","author":"Durdagi","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.cyto.2025.157010_bb0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174196","article-title":"Role of leukotriene pathway and montelukast in pulmonary and extrapulmonary manifestations of COVID-19: the enigmatic entity","volume":"904","author":"Al-kuraishy","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.cyto.2025.157010_bb0280","doi-asserted-by":"crossref","DOI":"10.3390\/children9111783","article-title":"Adverse drug reactions (ADRs) of Montelukast in children","volume":"9","author":"Al-Shamrani","year":"2022","journal-title":"Children"},{"key":"10.1016\/j.cyto.2025.157010_bb0285","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/cpdd.1485","article-title":"Pharmacokinetics and bioequivalence of two formulations of Montelukast sodium tablets in healthy Chinese volunteers under fasting and fed conditions","volume":"14","author":"Rao","year":"2025","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.cyto.2025.157010_bb0290","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1111\/cns.12596","article-title":"Cysteinyl leukotrienes and their receptors: emerging therapeutic targets in central nervous system disorders","volume":"22","author":"Ghosh","year":"2016","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.cyto.2025.157010_bb0295","article-title":"Neuroprotection by montelukast against rotenone-induced rat brain damage","volume":"10","author":"Abdel-Salam","year":"2018","journal-title":"React. Oxyg. Species"},{"key":"10.1016\/j.cyto.2025.157010_bb0300","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12974-023-02714-z","article-title":"Exploring the neuroprotective effects of montelukast on brain inflammation and metabolism in a rat model of quinolinic acid-induced striatal neurotoxicity","volume":"20","author":"Tassan Mazzocco","year":"2023","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.cyto.2025.157010_bb0305","doi-asserted-by":"crossref","first-page":"8466","DOI":"10.1038\/ncomms9466","article-title":"Structural and functional rejuvenation of the aged brain by an approved anti-asthmatic drug","volume":"6","author":"Marschallinger","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cyto.2025.157010_bb0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2022.105922","article-title":"Deficiency of astrocyte CysLT1R ameliorates depression-like behaviors in mice by modulating glutamate synaptic transmission","volume":"175","author":"Liu","year":"2022","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.cyto.2025.157010_bb0315","doi-asserted-by":"crossref","DOI":"10.3390\/biom12030346","article-title":"Leukotriene signaling as a target in \u03b1-Synucleinopathies","volume":"12","author":"Strempfl","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.cyto.2025.157010_bb0320","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41398-017-0017-2","article-title":"The direct role of 5-lipoxygenase on tau pathology, synaptic integrity and cognition in a mouse model of tauopathy","volume":"7","author":"Vagnozzi","year":"2017","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.cyto.2025.157010_bb0325","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1096\/fj.07-9131.com","article-title":"5-lipoxygenase gene disruption reduces amyloid-\u03b2 pathology in a mouse model of Alzheimer\u2019s disease","volume":"22","author":"Firuzi","year":"2008","journal-title":"FASEB J."},{"key":"10.1016\/j.cyto.2025.157010_bb0330","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1007\/s13311-020-00836-3","article-title":"The leukotriene receptor antagonist Montelukast reduces alpha-Synuclein load and restores memory in an animal model of dementia with Lewy bodies","volume":"17","author":"Marschallinger","year":"2020","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.cyto.2025.157010_bb0335","first-page":"403","article-title":"Montelukast reduces eosinophilic inflammation by inhibiting both epithelial cell cytokine secretion (GM-CSF, IL-6, IL-8) and eosinophil survival","volume":"24","author":"Mullol","year":"2010","journal-title":"J. Biol. Regul. Homeost. Agents"},{"key":"10.1016\/j.cyto.2025.157010_bb0340","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.neuint.2013.01.002","article-title":"Leukotriene D4 induces amyloid-\u03b2 generation via CysLT 1R-mediated NF-\u03baB pathways in primary neurons","volume":"62","author":"Wang","year":"2013","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.cyto.2025.157010_bb0345","doi-asserted-by":"crossref","DOI":"10.1038\/srep18286","article-title":"Inflammatory eicosanoids increase amyloid precursor protein expression via activation of multiple neuronal receptors","volume":"5","author":"Herbst-Robinson","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cyto.2025.157010_bb0350","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.neuint.2014.05.006","article-title":"Montelukast rescues primary neurons against A\u03b21-42-induced toxicity through inhibiting CysLT1R-mediated NF-\u03baB signaling","volume":"75","author":"Lai","year":"2014","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.cyto.2025.157010_bb0355","doi-asserted-by":"crossref","first-page":"12720","DOI":"10.1038\/s41598-025-91785-4","article-title":"The anti-inflammatory drug Montelukast ameliorates cognitive deficits by rescuing the inflammatory levels in young AD animal models","volume":"15","author":"Wu","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cyto.2025.157010_bb0360","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s11096-020-01160-8","article-title":"A possible effect of montelukast on neurological aging examined by the use of register data","volume":"43","author":"Grinde","year":"2021","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.1016\/j.cyto.2025.157010_bb0365","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2174\/1874205X01711010007","article-title":"Case series using Montelukast in patients with memory loss and dementia","volume":"11","author":"Rozin","year":"2017","journal-title":"Open Neurol. J."},{"key":"10.1016\/j.cyto.2025.157010_bb0370","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/imm.13308","article-title":"Montelukast alleviates inflammation in experimental autoimmune encephalomyelitis by altering Th17 differentiation in a mouse model","volume":"163","author":"Han","year":"2021","journal-title":"Immunology"},{"key":"10.1016\/j.cyto.2025.157010_bb0375","doi-asserted-by":"crossref","DOI":"10.1111\/cns.70167","article-title":"The compelling role of brain-derived neurotrophic factor signaling in multiple sclerosis: role of BDNF activators","volume":"30","author":"Al-kuraishy","year":"2024","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.cyto.2025.157010_bb0380","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1111\/bph.16408","article-title":"Montelukast improves disease outcome in SOD1G93A female mice by counteracting oligodendrocyte dysfunction and aberrant glial reactivity","volume":"181","author":"Raffaele","year":"2024","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.cyto.2025.157010_bb0385","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.neuroscience.2010.08.039","article-title":"Protective effect of montelukast against quinolinic acid\/malonic acid induced neurotoxicity: possible behavioral, biochemical, mitochondrial and tumor necrosis factor-\u03b1 level alterations in rats","volume":"171","author":"Kalonia","year":"2010","journal-title":"Neuroscience"},{"key":"10.1016\/j.cyto.2025.157010_bb0390","doi-asserted-by":"crossref","DOI":"10.1590\/1414-431X20155031","article-title":"Montelukast reduces seizures in pentylenetetrazol-kindled mice","volume":"49","author":"Fleck","year":"2016","journal-title":"Braz. J. Med. Biol. Res."},{"key":"10.1016\/j.cyto.2025.157010_bb0395","doi-asserted-by":"crossref","DOI":"10.3390\/ph15091147","article-title":"Montelukast and acute coronary syndrome: the endowed drug","volume":"15","author":"Alomair","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.cyto.2025.157010_bb0400","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s11064-023-04064-x","article-title":"The possible role of brain-derived neurotrophic factor in epilepsy","volume":"49","author":"AlRuwaili","year":"2024","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.cyto.2025.157010_bb0405","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s10787-019-00611-7","article-title":"Cysteinyl leukotriene receptor type 1 antagonist montelukast protects against injury of blood\u2013brain barrier","volume":"27","author":"Zhou","year":"2019","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.cyto.2025.157010_bb0410","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/WNR.0000000000000740","article-title":"Montelukast treatment protects nigral dopaminergic neurons against microglial activation in the 6-hydroxydopamine mouse model of Parkinson\u2019s disease","volume":"28","author":"Jang","year":"2017","journal-title":"Neuroreport"},{"key":"10.1016\/j.cyto.2025.157010_bb0415","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2024.176851","article-title":"Sigma-1 receptor modulation by clemastine highlights its repurposing as neuroprotective agent against seizures and cognitive deficits in PTZ-kindled rats","volume":"980","author":"Badawi","year":"2024","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.cyto.2025.157010_bb0420","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.taap.2018.09.012","article-title":"Montelukast attenuates rotenone-induced microglial activation\/p38 MAPK expression in rats: possible role of its antioxidant, anti-inflammatory and antiapoptotic effects","volume":"358","author":"Mansour","year":"2018","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.cyto.2025.157010_bb0425","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1002\/ana.26638","article-title":"\u03b22-Adrenoreceptor agonists, Montelukast, and Parkinson disease risk","volume":"93","author":"Liu","year":"2023","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.cyto.2025.157010_bb0430","first-page":"52","article-title":"Expression and distribution of cysteinyl leukotriene receptors CysLT1R and CysLT2R, and GPR17 in brain of Parkinson disease model mice","volume":"42","author":"Wang","year":"2013","journal-title":"Zhejiang Da Xue Xue Bao Yi Xue Ban"},{"key":"10.1016\/j.cyto.2025.157010_bb0435","doi-asserted-by":"crossref","DOI":"10.1016\/B978-0-323-95698-7.00001-2","article-title":"Cytosolic phospholipase A2 (cPLA2)-mediated oxidative and inflammatory responses in neurodegenerative diseases","author":"Hegde","year":"2023","journal-title":"Phospholipases Physiol. Pathol."},{"key":"10.1016\/j.cyto.2025.157010_bb0440","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2023.116387","article-title":"Pentoxifylline and thiamine ameliorate rhabdomyolysis-induced acute kidney injury in rats via suppressing TLR4\/NF-\u03baB and NLRP-3\/caspase-1\/gasdermin mediated-pyroptosis","volume":"461","author":"Al-Kharashi","year":"2023","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.cyto.2025.157010_bb0445","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2025.177830","article-title":"LRP1 at the crossroads of Parkinson's and Alzheimer's: divergent roles in \u03b1-synuclein and amyloid pathology","volume":"1002","author":"Alshahrani","year":"2025","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.cyto.2025.157010_bb0450","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1096\/fj.02-0314fje","article-title":"Activation of microglia by human neuromelanin is NF-kappaB dependent and involves p38 mitogen-activated protein kinase: implications for Parkinson\u2019s disease","volume":"17","author":"Wilms","year":"2003","journal-title":"FASEB J."},{"key":"10.1016\/j.cyto.2025.157010_bb0455","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13041-018-0418-z","article-title":"EriB targeted inhibition of microglia activity attenuates MPP+ induced da neuron injury through the NF-\u03baB signaling pathway","volume":"11","author":"Dou","year":"2018","journal-title":"Mol. Brain"},{"key":"10.1016\/j.cyto.2025.157010_bb0460","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3109\/15376516.2011.560210","article-title":"\u03b1-Synuclein overexpression enhances manganese-induced neurotoxicity through the NF-\u03baB-mediated pathway","volume":"21","author":"Prabhakaran","year":"2011","journal-title":"Toxicol. Mech. Methods"},{"key":"10.1016\/j.cyto.2025.157010_bb0465","doi-asserted-by":"crossref","first-page":"24503","DOI":"10.1039\/D4RA04496G","article-title":"In vivo determination of analgesic and anti-inflammatory activities of isolated compounds from Cleome amblyocarpa and molecular modelling for the top active investigated compounds","volume":"14","author":"El-Ayouty","year":"2024","journal-title":"RSC Adv."},{"key":"10.1016\/j.cyto.2025.157010_bb0470","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/7905486","article-title":"P-glycoprotein (ABCB1) and oxidative stress: focus on Alzheimer\u21d4s disease","volume":"2017","author":"Sita","year":"2017","journal-title":"Oxidative Med. Cell. Longev."},{"key":"10.1016\/j.cyto.2025.157010_bb0475","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/S1081-1206(10)61326-9","article-title":"Effect of montelukast on nuclear factor \u03baB activation and proinflammatory molecules","volume":"94","author":"Maeba","year":"2005","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"10.1016\/j.cyto.2025.157010_bb0480","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2019.108915","article-title":"Zafirlukast protects blood-brain barrier integrity from ischemic brain injury","volume":"316","author":"Zeng","year":"2020","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.cyto.2025.157010_bb0485","article-title":"Common NLRP3 inflammasome inhibitors and Covid-19: divide and conquer","volume":"18","author":"Batiha","year":"2022","journal-title":"Sci. Afr."},{"key":"10.1016\/j.cyto.2025.157010_bb0490","first-page":"1","article-title":"A novel treatment strategy by natural products in NLRP3 inflammasome-mediated neuroinflammation in Alzheimer's and Parkinson's disease","volume":"22","author":"Lee","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cyto.2025.157010_bb0495","doi-asserted-by":"crossref","DOI":"10.1186\/s12974-019-1670-6","article-title":"Systemic activation of NLRP3 inflammasome and plasma \u03b1-synuclein levels are correlated with motor severity and progression in Parkinson\u2019s disease","volume":"17","author":"Fan","year":"2020","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.cyto.2025.157010_bb0500","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.120707","article-title":"Ameliorative effect of montelukast against carbon tetrachloride-induced hepatotoxicity: targeting NLRP3 inflammasome pathway","volume":"304","author":"El-Kashef","year":"2022","journal-title":"Life Sci."},{"key":"10.1016\/j.cyto.2025.157010_bb0505","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10753-022-01721-1","article-title":"Neuroinflammation in Alzheimer\u2019s disease: current Progress in molecular signaling and therapeutics","volume":"46","author":"Thakur","year":"2023","journal-title":"Inflammation"},{"key":"10.1016\/j.cyto.2025.157010_bb0510","doi-asserted-by":"crossref","DOI":"10.1186\/s13024-018-0273-5","article-title":"A new hypothesis for Parkinson\u2019s disease pathogenesis: GTPase-p38 MAPK signaling and autophagy as convergence points of etiology and genomics","volume":"13","author":"Obergasteiger","year":"2018","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.cyto.2025.157010_bb0515","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1515\/tnsci-2018-0022","article-title":"P38 mitogen-activated protein kinase and Parkinson\u2019s disease","volume":"9","author":"He","year":"2018","journal-title":"Transl. Neurosci."},{"key":"10.1016\/j.cyto.2025.157010_bb0520","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1213\/ANE.0000000000000174","article-title":"Montelukast attenuates neuropathic pain through inhibiting p38 mitogen-activated protein kinase and nuclear factor-kappa b in a rat model of chronic constriction injury","volume":"118","author":"Zhou","year":"2014","journal-title":"Anesth. Analg."},{"key":"10.1016\/j.cyto.2025.157010_bb0525","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12964-023-01402-y","article-title":"The involvement of \u03b1-synucleinopathy in the disruption of microglial homeostasis contributes to the pathogenesis of Parkinson's disease","volume":"22","author":"Miao","year":"2024","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.cyto.2025.157010_bb0530","doi-asserted-by":"crossref","first-page":"914","DOI":"10.3390\/ph15080914","article-title":"Leukotriene receptor antagonist, Montelukast ameliorates L-NAME-induced pre-eclampsia in rats through suppressing the IL-6\/Jak2\/STAT3 signaling pathway","volume":"15","author":"Abdelzaher","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.cyto.2025.157010_bb0535","doi-asserted-by":"crossref","first-page":"283","DOI":"10.5607\/en.2013.22.4.283","article-title":"Mitochondrial dysfunction of immortalized human adipose tissue-derived mesenchymal stromal cells from patients with Parkinson\u2019s disease","volume":"22","author":"Moon","year":"2013","journal-title":"Exp. Neurobiol."},{"key":"10.1016\/j.cyto.2025.157010_bb0540","doi-asserted-by":"crossref","DOI":"10.3389\/fnana.2015.00091","article-title":"Oxidative stress and Parkinson\u2019s disease","volume":"9","author":"Blesa","year":"2015","journal-title":"Front. Neuroanat."},{"issue":"Suppl. 4","key":"10.1016\/j.cyto.2025.157010_bb0545","first-page":"406","article-title":"Mitochondrial dysfunction in Parkinson\u2019s disease","volume":"60","author":"Hattori","year":"2002","journal-title":"Nippon Rinsho. Japanese J. Clin. Med."},{"key":"10.1016\/j.cyto.2025.157010_bb0550","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.3390\/ijms14022388","article-title":"Parkinson\u2019s disease: a complex interplay of mitochondrial DNA alterations and oxidative stress","volume":"14","author":"Ciccone","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cyto.2025.157010_bb0555","doi-asserted-by":"crossref","first-page":"19126","DOI":"10.1073\/pnas.0508215102","article-title":"Complex I deficiency primes Bax-dependent neuronal apoptosis through mitochondrial oxidative damage","volume":"102","author":"Perier","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.cyto.2025.157010_bb0560","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.pathophys.2011.02.003","article-title":"Montelukast, a leukotriene receptor antagonist abrogates lipopolysaccharide-induced toxicity and oxidative stress in rat liver","volume":"18","author":"Mohamadin","year":"2011","journal-title":"Pathophysiology"},{"key":"10.1016\/j.cyto.2025.157010_bb0565","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/9396425","article-title":"Resveratrol and Montelukast alleviate Paraquat-induced hepatic injury in mice: modulation of oxidative stress, inflammation, and apoptosis","volume":"2017","author":"El-Boghdady","year":"2017","journal-title":"Oxidative Med. Cell. Longev."},{"key":"10.1016\/j.cyto.2025.157010_bb0570","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.1080\/21691401.2019.1687502","article-title":"Montelukast promotes mitochondrial biogenesis via CREB\/PGC-1\u03b1 in human bronchial epithelial cells","volume":"47","author":"Wang","year":"2019","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"10.1016\/j.cyto.2025.157010_bb0575","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.2174\/0118715273258337230925040049","article-title":"Montelukast ameliorates scopolamine-induced Alzheimer's disease: role on cholinergic neurotransmission, antioxidant defence system, neuroinflammation and expression of BDNF","volume":"23","author":"Yerraguravagari","year":"2023","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"10.1016\/j.cyto.2025.157010_bb0580","doi-asserted-by":"crossref","first-page":"e22231","DOI":"10.1002\/jbt.22231","article-title":"Montelukast abrogates prednisolone-induced hepatic injury in rats: modulation of mitochondrial dysfunction, oxidative\/nitrosative stress, and apoptosis","volume":"33","author":"Hegab","year":"2019","journal-title":"J. Biochem. Mol. Toxicol."},{"key":"10.1016\/j.cyto.2025.157010_bb0585","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/15548627.2023.2259281","article-title":"The beneficial role of autophagy in multiple sclerosis: yes or no?","volume":"20","author":"Al-kuraishy","year":"2024","journal-title":"Autophagy"},{"key":"10.1016\/j.cyto.2025.157010_bb0590","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1016\/j.jmb.2020.01.037","article-title":"Autophagy in Parkinson\u2019s disease","volume":"432","author":"Hou","year":"2020","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.cyto.2025.157010_bb0595","doi-asserted-by":"crossref","first-page":"728","DOI":"10.3390\/ijms20030728","article-title":"Balancing mTOR signaling and autophagy in the treatment of Parkinson\u2019s disease","volume":"20","author":"Zhu","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cyto.2025.157010_bb0600","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1001\/archneurol.2010.198","article-title":"Chaperone-mediated autophagy markers in Parkinson disease brains","volume":"67","author":"Alvarez-Erviti","year":"2010","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.cyto.2025.157010_bb0605","doi-asserted-by":"crossref","first-page":"9769","DOI":"10.1074\/jbc.C400557200","article-title":"The stress-inducted proteins RTP801 and RTP801L are negative regulators of the mammalian target of rapamycin pathway","volume":"280","author":"Corradetti","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cyto.2025.157010_bb0610","doi-asserted-by":"crossref","first-page":"14363","DOI":"10.1523\/JNEUROSCI.3928-08.2008","article-title":"RTP801 is induced in Parkinson\u2019s disease and mediates neuron death by inhibiting Akt phosphorylation\/activation","volume":"28","author":"Malagelada","year":"2008","journal-title":"J. Neurosci."},{"key":"10.1016\/j.cyto.2025.157010_bb0615","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1097\/WNR.0000000000000871","article-title":"Triggering of inflammasome by impaired autophagy in response to acute experimental Parkinson\u2019s disease: involvement of the PI3K\/Akt\/mTOR pathway","volume":"28","author":"Giacoppo","year":"2017","journal-title":"Neuroreport"},{"key":"10.1016\/j.cyto.2025.157010_bb0620","doi-asserted-by":"crossref","first-page":"4366","DOI":"10.1158\/0008-5472.CAN-10-1769","article-title":"Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1","volume":"71","author":"Ben Sahra","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.cyto.2025.157010_bb0625","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2014.175","article-title":"Metformin lowers Ser-129 phosphorylated \u03b1-synuclein levels via mTOR-dependent protein phosphatase 2A activation","volume":"5","author":"P\u00e9rez-Revuelta","year":"2014","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.cyto.2025.157010_bb0630","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.120865","article-title":"Preferential effect of Montelukast on Dapagliflozin: modulation of IRS-1\/AKT\/GLUT4 and ER stress response elements improves insulin sensitivity in soleus muscle of a type-2 diabetic rat model","volume":"307","author":"Fleifel","year":"2022","journal-title":"Life Sci."},{"key":"10.1016\/j.cyto.2025.157010_bb0635","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3892\/mmr.2024.13265","article-title":"Differential effects of montelukast and zafirlukast on MDA-MB-231 triple-negative breast cancer cells: cell cycle regulation, apoptosis, autophagy, DNA damage and endoplasmic reticulum stress","volume":"30","author":"Vivithanaporn","year":"2024","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.cyto.2025.157010_bb0640","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1166\/mex.2024.2596","article-title":"Mechanism of montelukast on autophagy and apoptosis of airway epithelial cells through STAT3-ROR \u03b3 t-IL-17\/IL-23 signaling pathway","volume":"14","author":"Xu","year":"2023","journal-title":"Mater. Express"}],"container-title":["Cytokine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466625001577?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466625001577?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T10:43:50Z","timestamp":1772880230000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043466625001577"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":128,"alternative-id":["S1043466625001577"],"URL":"https:\/\/doi.org\/10.1016\/j.cyto.2025.157010","relation":{},"ISSN":["1043-4666"],"issn-type":[{"value":"1043-4666","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dysregulation of the leukotriene pathway in Parkinson's disease: The potential role of montelukast","name":"articletitle","label":"Article Title"},{"value":"Cytokine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cyto.2025.157010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"157010"}}